Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older

Journal of Thoracic Oncology

Volumn 7, Issue 2, 2012, Pages 412-418

  Chen, Yuh Min ^a,b,c   Tsai, Chun Ming ^a   Fan, Wen Chien ^a   Shih, Jen Fu ^a   Liu, Shih Hao ^d   Wu, Chieh Hung ^a   Chou, Teh Ying ^d   Lee, Yu Chin ^a   Perng, Reury Perng ^a   Whang Peng, Jacqueline ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Nonsmall cell lung cancer; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVELBINE;

ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY SCALE; GENE MUTATION; GROUPS BY AGE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR GENE; SURVIVAL TIME; TAIWAN; TREATMENT OUTCOME; VOMITING; WILD TYPE;

EID: 84858339030     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31823a39e8     Document Type: Article

References (27)

1. Schottenfeld D. Etiology and epidemiology of lung cancer. In HI Pass, JB Mitchell, DH Johnson, et al. (Eds)., Lung Cancer - Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2000. Pp. 367-388.
2. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 2007;25:5570-5577.
3. Kuo CW, Chen YM, Chao JY, et al. Non-small cell lung cancer in very young and very old patients. Chest 2000;117:354-357.
4. Chen YM, Perng RP, Shih JF, et al. Chemotherapy for non-small-cell lung cancer in elderly patients. Chest 2005;128:132-139.
5. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181. (Pubitemid 34162751)
6. Azzoli CG, Baker Jr S, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
7. The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
8. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372. (Pubitemid 36395256)
9. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007;25:1898-1907. (Pubitemid 46854424)
10. Gridelli C, Maionea P, Rossia A, et al. Treatment of advanced nonsmall-cell lung cancer in the elderly. Lung Cancer 2009;66:282-286.
11. Chen YM, Perng RP, Shih JF, et al. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. Lung Cancer 2008;61:214-219.
12. Chen YM, Yu CJ, Yang CH, et al. A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 2007;56:89-95.
13. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
14. Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
15. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naïve patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766. (Pubitemid 350002874)
16. Swinson D, Williams S, Beddard K, et al. Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancer. J Clin Oncol 2005 ASCO Annual Meeting Proceedings Part I;23:(Abstract 7256).
17. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26: 4253-4260.
18. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2. J Clin Oncol 2008;26: 863-869. (Pubitemid 351398077)
19. Ebi N, Semba H, Tokunaga S, et al. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:1166-1171.
20. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
21. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
22. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
23. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
25. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381. (Pubitemid 16163075)
26. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-smallcell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663. (Pubitemid 46630541)
27. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010 ASCO Annual Meeting Proceedings Part I;28:(Abstract 2).